AHMEDABAD, India, Nov. 3, 2022 /PRNewswire/ — Syna Therapeutics, a three way partnership of Reig Jofre and Leanbio, has signed a world rights licensing deal with Intas Pharmaceuticals Ltd. to commercialise its biosimilar drug LB-0702. Under the phrases of the settlement, Intas has been granted unique licensing rights to commercialize LB-0702 worldwide. Syna will develop and manufacture LB-0702 and provide the product to Intas and its worldwide associates. As one of many key gamers in the worldwide biosimilar market, Accord Healthcare, Intas’ wholly-owned subsidiary, has confirmed business capabilities with one of many largest gross sales and distribution networks in 85 international locations globally.
Syna will start medical trials for LB-0702 in 2023 with assist from its companions Leanbio and Reig Jofre. The firm will utilise the know-how platforms of Leanbio coupled with the know-how manufacturing experience of Reig Jofre at its new manufacturing plant in Barcelona, which is purposed for sterile injectables and lyophilised biopharmaceutical merchandise.
“Signing this deal is one of Syna’s most important milestones since the company was founded in 2018 and it confirms the pharmaceutical industry and healthcare systems’ growing interest in biosimilar drugs,” notes Dr Andreu Soldevila, co-founder and CEO of Syna. “We are delighted with this agreement with Intas because we believe biosimilar LB-0702 will have a very positive impact on healthcare systems. Accord Healthcare, Intas’ wholly-owned subsidiary is the ideal partner to commercialize our biosimilar in global markets. With this collaboration, we are committed to further strengthening the value of our biosimilar programs in global markets,” he added.
Binish Chudgar, Vice Chairman & Managing Director of Intas Pharmaceuticals, commented, “We are pleased to announce this agreement with Syna Therapeutics. This agreement sets out Accord Healthcare to file for global rights for this critical drug and is in line with our long-term strategy, reinforcing our commitment to improving access to high-quality biosimilar drugs for patients globally.”
About Syna Therapeutics
Syna Therapeutics is a three way partnership fashioned by Reig Jofre and Leanbio to develop high-quality biosimilars and progressive molecules to reply to the rising international demand for organic remedies. Syna has intensive expertise and know-how in all phases of biosimilar medicines, masking the whole worth chain to allow biosimilars to attain sufferers: cell financial institution creation, pharma growth of the completed product, industrial manufacturing, and advertising and marketing or license agreements. Founded in 2018, Syna has its headquarters on the Barcelona Science Park. For extra info, please go to synatherapeutics.com
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Ltd. is a number one vertically built-in pharmaceutical firm based mostly in Ahmedabad, India, having end-to-end capabilities of formulation growth, manufacturing and advertising and marketing alongside with backward integration of APIs. The organisation has greater than 18,000 staff and 14 manufacturing websites worldwide and sells merchandise in greater than 85 international locations. The Intas Group’s income amounted to USD 2.5 bn in FY 2021-22 and the compounded annual progress fee of income has been 22% in the previous 5 years. For extra info, please go to www.intaspharma.com.
About Reig Jofre
Reig Jofre is a pharmaceutical firm listed on the Spanish Stock Exchange market (RJF) devoted to the R&D, manufacture and advertising and marketing of pharmaceutical merchandise and meals dietary supplements. Its exercise is structured into three business models: Pharmaceutical Technologies (sterile injectables, lyophilised merchandise and antibiotics), Speciality Pharmacare (dermatology, osteoarticular, ladies’s well being and paediatrics) and Consumer Healthcare (meals dietary supplements and OTC merchandise). Founded in 1929 in Barcelona (Spain), Reig Jofre has over 1,100 staff, 4 growth and manufacturing centres in Europe and subsidiaries in 8 international locations. In 2021, the corporate’s turnover was €236.2 million. More info: reigjofre.com
About Leanbio
Leanbio is a market-orientated Contract Development and Manufacturing Organisation (CDMO) that develops and manufactures biopharmaceutical merchandise and new organic entities and biosimilars, utilizing the Lean manufacturing and Quality by Design (QbD) method to maximise success and lower time to market, prices and dangers. Founded in 2014 by Dr Andreu Soldevila and Dr Albert Font, the corporate has 4 know-how platforms and cutting-edge services on the Barcelona Science Park. More info: leanbiopro.com
For extra info, please contact:
Ms. Vibhuti Bhatt
Director
One Advertising & Communication Services Ltd.
Mobile: +91-9824079734
Email: [email protected]
